IL141011A0 - Hepatitis c inhibitor peptides - Google Patents

Hepatitis c inhibitor peptides

Info

Publication number
IL141011A0
IL141011A0 IL14101199A IL14101199A IL141011A0 IL 141011 A0 IL141011 A0 IL 141011A0 IL 14101199 A IL14101199 A IL 14101199A IL 14101199 A IL14101199 A IL 14101199A IL 141011 A0 IL141011 A0 IL 141011A0
Authority
IL
Israel
Prior art keywords
hepatitis
inhibitor peptides
peptides
inhibitor
Prior art date
Application number
IL14101199A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Ca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ca Ltd filed Critical Boehringer Ingelheim Ca Ltd
Publication of IL141011A0 publication Critical patent/IL141011A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14101199A 1998-08-10 1999-08-09 Hepatitis c inhibitor peptides IL141011A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9594598P 1998-08-10 1998-08-10
PCT/CA1999/000737 WO2000009558A1 (en) 1998-08-10 1999-08-09 Hepatitis c inhibitor peptides

Publications (1)

Publication Number Publication Date
IL141011A0 true IL141011A0 (en) 2002-02-10

Family

ID=22254308

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14101199A IL141011A0 (en) 1998-08-10 1999-08-09 Hepatitis c inhibitor peptides
IL141011A IL141011A (en) 1998-08-10 2001-01-22 Hepatitis c inhibitor peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141011A IL141011A (en) 1998-08-10 2001-01-22 Hepatitis c inhibitor peptides

Country Status (33)

Country Link
EP (1) EP1105422B1 (cs)
JP (1) JP4435982B2 (cs)
KR (1) KR100629791B1 (cs)
CN (1) CN1166690C (cs)
AR (1) AR022061A1 (cs)
AT (1) ATE317854T1 (cs)
AU (1) AU764655B2 (cs)
BG (1) BG64956B1 (cs)
BR (1) BR9912943A (cs)
CA (1) CA2336597C (cs)
CO (1) CO5180537A1 (cs)
CZ (1) CZ301405B6 (cs)
DE (1) DE69929887T2 (cs)
DK (1) DK1105422T3 (cs)
EA (1) EA004765B1 (cs)
EE (1) EE200100080A (cs)
ES (1) ES2257066T3 (cs)
HK (1) HK1039947B (cs)
HR (1) HRP20010101A2 (cs)
HU (1) HUP0104548A3 (cs)
ID (1) ID27784A (cs)
IL (2) IL141011A0 (cs)
MY (1) MY125014A (cs)
NO (1) NO20010604L (cs)
NZ (1) NZ510395A (cs)
PL (1) PL199419B1 (cs)
RS (1) RS49819B (cs)
SK (1) SK286846B6 (cs)
TR (1) TR200100438T2 (cs)
TW (1) TW577895B (cs)
UA (1) UA73480C2 (cs)
WO (1) WO2000009558A1 (cs)
ZA (1) ZA200100972B (cs)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
RU2002129564A (ru) * 2000-04-05 2004-05-10 Шеринг Корпорейшн (US) Макроциклические ингибиторы сериновой ns3-протеазы, включающие n-циклические р2 структурные элементы вируса гепатита с
AU2001253621A1 (en) 2000-04-19 2001-11-07 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
PL365695A1 (en) 2000-07-21 2005-01-10 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
MY139078A (en) 2000-07-21 2009-08-28 Schering Corp Peptides as ns3-serine protease inhibitors of hepatitis c virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
AR031905A1 (es) 2000-12-12 2003-10-08 Schering Corp Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c
MXPA04000293A (es) 2001-07-11 2004-05-04 Vertex Pharma Inhibidores de serina proteasa biciclica de puente.
NZ531681A (en) * 2001-10-24 2007-05-31 Vertex Pharma Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
PE20030857A1 (es) * 2002-01-23 2003-10-25 Schering Corp Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
RU2004133044A (ru) 2002-04-11 2006-01-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Ингибиторы сериновых протеаз, в частности, протеазы ns3-ns4a hcv
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2003099316A1 (en) 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
PL215228B1 (pl) 2002-05-20 2013-11-29 Bristol Myers Squibb Co Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
WO2004101605A1 (en) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
KR100971347B1 (ko) * 2003-03-08 2010-07-20 주식회사유한양행 씨형 간염바이러스 감염 치료용 엔에스3 프로테아제 억제제
JP4231524B2 (ja) * 2003-04-10 2009-03-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大環状化合物の製造方法
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
DK1654261T3 (da) 2003-05-21 2008-01-14 Boehringer Ingelheim Int Hepatitis C-inhibitorforbindelser
US7449447B2 (en) 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
UY28500A1 (es) 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
JP4704342B2 (ja) 2003-09-22 2011-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対し活性な大環状ペプチド
WO2005030796A1 (en) 2003-09-26 2005-04-07 Schering Corporation Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
MXPA06003963A (es) 2003-10-14 2006-08-25 Intermune Inc Acidos carboxilicos macrociclicos y acilsulfonamidas como inhibidores de replicacion del hcv.
CN1894276B (zh) 2003-10-27 2010-06-16 威特克斯医药股份有限公司 Hcv ns3-ns4a蛋白酶抗药性突变体
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005051980A1 (en) * 2003-11-20 2005-06-09 Schering Corporation Depeptidized inhibitors of hepatitis c virus ns3 protease
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005056182A1 (en) 2003-12-08 2005-06-23 Boehringer Ingelheim International, Gmbh Removal of ruthenium by-product by supercritical fluid processing
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
DE602005017582D1 (en) 2004-01-30 2009-12-24 Medivir Ab Hcv ns-3 serine protease inhibitoren
AU2005215829C1 (en) 2004-02-20 2012-08-30 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
PL1719773T3 (pl) 2004-02-24 2009-08-31 Japan Tobacco Inc Skondensowane związki heterotetracykliczne i ich zastosowanie jako inhibitora polimerazy HCV
JP4745327B2 (ja) 2004-02-27 2011-08-10 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
RS51394B (en) 2004-02-27 2011-02-28 Schering Corporation SUMPOR COMPOUNDS AS INHIBITORS OF NS3 SERINE PROTEASE HEPATITIS C VIRUS
WO2005087730A1 (en) * 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
TW200529823A (en) 2004-02-27 2005-09-16 Schering Corp Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
EP1748983A2 (en) 2004-02-27 2007-02-07 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
RU2006136084A (ru) 2004-03-15 2008-04-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Способ получения микроциклических соединений
AP2006003763A0 (en) * 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
WO2005113581A1 (en) 2004-05-20 2005-12-01 Schering Corporation Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
WO2005116054A1 (en) 2004-05-25 2005-12-08 Boehringer Ingelheim International, Gmbh Process for preparing acyclic hcv protease inhibitors
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2573346C (en) 2004-07-20 2011-09-20 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7550559B2 (en) 2004-08-27 2009-06-23 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
WO2006030892A1 (ja) * 2004-09-17 2006-03-23 Nippon Shinyaku Co., Ltd. 複素環化合物の製造方法
SG191661A1 (en) 2004-10-01 2013-07-31 Vertex Pharma Hcv ns3-ns4a protease inhibition
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2600367C (en) 2005-03-08 2014-08-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7569600B2 (en) 2005-05-13 2009-08-04 Virochem Pharma Inc. Compounds and methods for the treatment of prevention of Flavivirus infections
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102816170A (zh) 2005-07-25 2012-12-12 因特蒙公司 C型肝炎病毒复制的新颖大环抑制剂
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
JP5015154B2 (ja) 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
PL1934243T3 (pl) 2005-09-09 2011-10-31 Boehringer Ingelheim Int Proces metatezy z zamknięciem pierścienia w zastosowaniu do wytwarzania peptydów makrocyklicznych
ATE493409T1 (de) 2005-10-11 2011-01-15 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
CA2651762A1 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ596922A (en) 2006-11-15 2013-03-28 Virochem Pharma Inc Thiophene analogues for the treatment or prevention of Flavivirus infections
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101790524B (zh) 2007-06-29 2014-07-16 吉里德科学公司 抗病毒化合物
SG182979A1 (en) 2007-06-29 2012-08-30 Gilead Sciences Inc Antiviral compounds
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
MX2010006210A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
MX2010006313A (es) 2007-12-19 2010-06-25 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5529120B2 (ja) 2008-05-29 2014-06-25 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルス阻害剤
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2331538B1 (en) 2008-09-16 2014-04-16 Boehringer Ingelheim International GmbH Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2341924A4 (en) 2008-10-02 2013-01-23 David Gladstone Inst METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2750227A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CN102458444A (zh) 2009-05-13 2012-05-16 英安塔制药有限公司 用作丙型肝炎病毒抑制剂的大环化合物
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
JP5476859B2 (ja) * 2009-08-25 2014-04-23 住友化学株式会社 光学活性な１−アミノ−２−エテニルシクロプロパン−１−カルボン酸エチルまたはその酸付加塩の製造方法、およびその製造方法に用いられる中間体
CA2781614A1 (en) 2009-11-25 2011-06-09 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
KR20120130173A (ko) 2009-12-24 2012-11-29 버텍스 파마슈티칼스 인코포레이티드 플라비바이러스 감염을 치료 또는 예방하기 위한 유사체들
AU2011209051B2 (en) 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
TW201139438A (en) 2010-03-24 2011-11-16 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
JP2013522377A (ja) 2010-03-24 2013-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染を処置または予防するためのアナログ
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
MX2012014918A (es) 2010-06-28 2013-04-08 Vertex Pharma Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus.
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
JP2013534249A (ja) 2010-08-17 2013-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
WO2012040167A1 (en) 2010-09-21 2012-03-29 Enanta Pharmaceuticals, Inc. Macrocyclic proline derived hcv serine protease inhibitors
BR112013008510A2 (pt) 2010-10-08 2016-07-05 Novartis Ag vitamina e formulações de inibidores de sulfamida ns3
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
JP2014506255A (ja) 2010-12-30 2014-03-13 エナンタ ファーマシューティカルズ インコーポレイテッド フェナントリジン大環状ｃ型肝炎セリンプロテアーゼ阻害剤
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20130338392A1 (en) * 2011-03-10 2013-12-19 Sumitomo Chemical Company, Limited Method of producing optically active 1-amino-2-vinylcyclopropane carboxylic acid ester
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012171332A1 (zh) 2011-06-16 2012-12-20 爱博新药研发(上海)有限公司 抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
CN102807607B (zh) * 2011-07-22 2013-10-23 爱博新药研发(上海)有限公司 抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
TW201313697A (zh) 2011-07-26 2013-04-01 Vertex Pharma 製備噻吩化合物之方法
EP2787999B1 (en) 2011-12-06 2019-01-23 The Board of Trustees of The Leland Stanford Junior University Methods and compositions for treating viral diseases
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
HUE031625T2 (en) 2012-10-19 2017-07-28 Bristol Myers Squibb Co 9-methyl substituted hexadecahydrocyclopropa(e)pyrrolo(1,2-a)(1,4)diazacyclopentadecinyl carbamate derivatives as non-structural 3 (ns3) protease inhibitors for the treatment of hepatitis c virus infections
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
CN113167802B (zh) 2018-12-04 2025-02-07 百时美施贵宝公司 通过多同位素体反应监测使用样品内校准曲线的分析方法
WO2023149981A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69709671T2 (de) * 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
NZ503262A (en) * 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.

Also Published As

Publication number Publication date
KR20010087179A (ko) 2001-09-15
PL199419B1 (pl) 2008-09-30
AU764655B2 (en) 2003-08-28
UA73480C2 (en) 2005-08-15
KR100629791B1 (ko) 2006-09-29
WO2000009558A1 (en) 2000-02-24
BG64956B1 (bg) 2006-10-31
CN1166690C (zh) 2004-09-15
NO20010604D0 (no) 2001-02-05
DK1105422T3 (da) 2006-06-19
IL141011A (en) 2009-09-01
BG105230A (en) 2001-10-31
AU5273299A (en) 2000-03-06
JP4435982B2 (ja) 2010-03-24
ATE317854T1 (de) 2006-03-15
EP1105422B1 (en) 2006-02-15
HK1039947A1 (en) 2002-05-17
SK2052001A3 (en) 2001-09-11
RS49819B (sr) 2008-08-07
EA004765B1 (ru) 2004-08-26
CZ301405B6 (cs) 2010-02-17
HUP0104548A3 (en) 2002-12-28
YU9301A (sh) 2005-06-10
PL346051A1 (en) 2002-01-14
JP2002522557A (ja) 2002-07-23
HK1039947B (zh) 2005-02-25
HUP0104548A2 (hu) 2002-04-29
MY125014A (en) 2006-07-31
EP1105422A1 (en) 2001-06-13
DE69929887T2 (de) 2006-08-24
SK286846B6 (sk) 2009-06-05
CZ2001515A3 (cs) 2001-07-11
CA2336597C (en) 2006-02-14
NO20010604L (no) 2001-02-05
BR9912943A (pt) 2001-05-08
EE200100080A (et) 2002-08-15
AR022061A1 (es) 2002-09-04
CO5180537A1 (es) 2002-07-30
ID27784A (id) 2001-04-26
TR200100438T2 (tr) 2001-06-21
NZ510395A (en) 2003-12-19
HRP20010101A2 (en) 2002-02-28
CA2336597A1 (en) 2000-02-24
EA200100229A1 (ru) 2001-10-22
ES2257066T3 (es) 2006-07-16
DE69929887D1 (en) 2006-04-20
CN1315965A (zh) 2001-10-03
TW577895B (en) 2004-03-01
ZA200100972B (en) 2002-07-18

Similar Documents

Publication Publication Date Title
DE69929887D1 (en) Hepatitis c inhibitor peptide
DE69940817D1 (en) Hepatitis c tripeptide inhibitoren
GB9707659D0 (en) Hepatitis C NS3 Protease inhibitors
PL344341A1 (en) Peptides
ZA98376B (en) Sulfamide-metalloprotease inhibitors
GB2321641B (en) Sulfamide-metalloprotease inhibitors
GB9718110D0 (en) Peptides
GB9825854D0 (en) Peptide
GB9700154D0 (en) Peptides
GB9800536D0 (en) Sequences
GB9812675D0 (en) Peptides
GB9807890D0 (en) Peptides
SI0952982T1 (en) Novel hepatitis b inhibitors
GB9800321D0 (en) Peptides
GB9827603D0 (en) Peptides
GB9818368D0 (en) Vitronectin-derived peptides
GB9717893D0 (en) Inhibitor
GB9707219D0 (en) Inhibitor
GB9818370D0 (en) Novel peptides
GB9705552D0 (en) Elastase inhibitor
IL121127A0 (en) Modified bowman-birk inhibitor
GB9808696D0 (en) Peptide derivatives
GB9709064D0 (en) Inhibitors
GB9713709D0 (en) Inhibitors
GB9703335D0 (en) Inhibitors